6.34
0.12 (1.93%)
| Previous Close | 6.22 |
| Open | 6.25 |
| Volume | 328,193 |
| Avg. Volume (3M) | 1,840,915 |
| Market Cap | 589,902,784 |
| Price / Earnings (Forward) | 54.95 |
| Price / Sales | 0.840 |
| Price / Book | 1.84 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -12.20% |
| Operating Margin (TTM) | -14.80% |
| Diluted EPS (TTM) | -1.12 |
| Quarterly Revenue Growth (YOY) | -3.10% |
| Total Debt/Equity (MRQ) | 22.36% |
| Current Ratio (MRQ) | 1.90 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 18.68 M |
| Return on Assets (TTM) | -5.26% |
| Return on Equity (TTM) | -13.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Myriad Genetics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.20 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 2.77% |
| % Held by Institutions | 104.21% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FOX JENNIFER LYNNE | - | 6.80 | -4,435 | -30,158 |
| Aggregate Net Quantity | -4,435 | |||
| Aggregate Net Value ($) | -30,158 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FOX JENNIFER LYNNE | Officer | 03 Sep 2025 | Disposed (-) | 4,435 | 6.80 | 30,158 |
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology |
| 03 Sep 2025 | Announcement | New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression |
| 27 Aug 2025 | Announcement | Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences |
| 20 Aug 2025 | Announcement | ANGLE Announces Collaboration with Myriad Genetics |
| 18 Aug 2025 | Announcement | Myriad Genetics Appoints Ben Wheeler Chief Financial Officer |
| 13 Aug 2025 | Announcement | New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results |
| 31 Jul 2025 | Announcement | Myriad Genetics Announces New $200 Million Credit Facility |
| 29 Jul 2025 | Announcement | Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 |
| 15 Jul 2025 | Announcement | Myriad Genetics Earns 2025 Great Place To Work Certification™ |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |